Dabigatran raises major bleeding risk

Dabigatran significantly raises the risk of major bleeding and gastrointestinal bleeding across all subgroups of patients with atrial fibrillation, and particularly in African Americans and patients...

Field of Interest: Gastroentero...
Type: News Item

‘Chemo brain’ may have targetable causes

BOSTON – The risk for cognitive decline following cancer treatment varies by both cancer and therapy types, and can range from subtle changes to severe deficits, according to a researcher. Patients...

Field of Interest: Oncology
Type: News Item

Vedolizumab rated first line for ulcerative colitis

VIENNA  – Vedolizumab, a second-line biologic for treating patients who have ulcerative colitis or Crohn’s disease and don’t respond to an anti-tumor necrosis factor drug, is gaining traction...

Field of Interest: Gastroentero...
Type: News Item

VIDEO: Don’t discount topical therapy for psoriasis

LAS VEGAS– Don’t underestimate the value of topical therapy for treating psoriasis patients, Dr. Linda Stein Gold said at Skin Disease Education Foundation’s annual Las Vegas dermatology...

Field of Interest: Dermatology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.